Table 2.
Demographic and Ocular Characteristics of the Study Population
| Characteristics | Total | Group A | Group B |
|---|---|---|---|
| Demographic | |||
| Eyes/participants, n | 53/38 | 27/20 | 26/18 |
| Age (y), mean ± SD | 55.6 ± 16.7 | 64.4 ± 15.1 | 45.8 ± 12.6 |
| Gender (female), n (%) | 17 (44.8) | 11 (55) | 6 (33.3) |
| Type 1 diabetes, n (%) | 15 (39.5) | 4 (20) | 11 (61.1) |
| Duration of diabetes (y), mean ± SD | 22.8 ± 9.5 | 23.3 ± 8.8 | 22.3 ± 10.4 |
| Hemoglobin A1c (%), mean ± SD | 7.9 ± 1.1 (n = 30) | 7.8 ± 1.2 (n = 16) | 8.2 ± 0.9 (n = 14) |
| Ocular (based on Spectralis HR scans) | |||
| CST (µm), mean ± SD | 342.9 ± 83.4 | 366 ± 100 | 320.3 ± 53.4 |
| DRIL extent (µm), mean ± SD | 264.2 ± 221.8 | 728 ± 216.6 | 152.8 ± 177.6 |
| By blurriness | 48.6 ± 120.1 | 602.9 ± 154.5 | 2.9 ± 8.9 |
| By cysts | 183.3 ± 179.1 | 673.9 ± 173.4 | 128.3 ± 178.0 |
| By hyperreflective foci | 36.4 ± 50.8 | 267.2 ± 65.8 | 22.4 ± 19.7 |
| Cyst area (µm2), mean ± SD | 20,155.5 ± 18,545.3 | 73,031.5 ± 20,443.2 | 10,125.2 ± 14,906.0 |
| COST visibility extent (µm), mean ± SD | 517.6 ± 370.1 | 876.5 ± 237.8 | 647.8 ± 360.3 |
| SRF horizontal extent (µm), mean ± SD | 37.0 ± 153.2 | 540.0 ± 130.7 | 0.0 ± 0.0 |
Group A: comparison of Spectralis HR versus Spectralis HR, Cirrus Cube, and Cirrus HD 5-Line; group B: comparison of Spectralis HR versus Optovue AngioVue.